TPST catalyst calendar

Tempest Therapeutics, Inc.

Upcoming catalysts
2
Cash runway
0.3 months
Cash & investments
$1M
Phase 3 programs
1

Tempest Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 11, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 0.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 11, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2028 A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy Trial Milestone Phase 3

Track TPST alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open TPST in the tracker

Recent history

DateEventTypePhase
September 28, 2026 8-K filed: Material agreement, Leadership change, Reg FD disclosure Corporate —
September 17, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
September 16, 2026 8-K filed: Other event Filing —
September 15, 2026 8-K filed: Material agreement Corporate —
August 24, 2026 8-K filed: Leadership change Corporate —
August 18, 2026 8-K filed: Other event Filing —
August 13, 2026 8-K filed: Material agreement Corporate —
August 13, 2026 Quarterly results filed (8-K) Earnings —
July 28, 2026 8-K filed: Other event Filing —
July 22, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
June 4, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
June 2, 2026 8-K filed: Material agreement Corporate —
May 29, 2026 8-K filed: Leadership change Corporate —
May 22, 2026 8-K filed: Leadership change Corporate —
May 22, 2026 8-K filed: Listing / standard notice Corporate —
May 14, 2026 Quarterly results filed (8-K) Earnings —
May 6, 2026 8-K filed: Reg FD disclosure, Other event Filing —
March 30, 2026 Quarterly results filed (8-K) Earnings —
March 23, 2026 8-K filed: Material agreement Corporate —
February 25, 2026 8-K filed: Reg FD disclosure, Other event Filing —
February 11, 2026 8-K filed: Reg FD disclosure Filing —
February 6, 2026 8-K filed: Material agreement, Acquisition completed, Leadership change Corporate —
January 28, 2026 8-K filed: Leadership change Corporate —
January 9, 2026 8-K filed: Listing / standard notice Corporate —
November 26, 2025 8-K filed: Other event Filing —
November 19, 2025 8-K filed: Material agreement, Leadership change, Other event Corporate —
November 5, 2025 Quarterly results filed (8-K) Earnings —
August 11, 2025 Quarterly results filed (8-K) Earnings —
June 12, 2025 8-K filed: Material agreement, Reg FD disclosure, Other event Corporate —
June 11, 2025 8-K filed: Other event Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.